Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1007-Breast,Adj,N1,Endocrine+/-Chemo | 1 | Y | 1 Recurrence Score testing | 9400 | 9383 | 0 | 0 | 0 | 0 | 0 | 02/28/2011 | 397 | 187 |
| 9383 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 2 | Y | 2 Chemo and Endocrine Therapy | 5000 | 2547 | 0 | 0 | 0 | 0 | 0 | 02/28/2011 | ||||
| 3 Endocrine Therapy Alone | 2536 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 5083 | 0 | 0 | 0 | 0 | 0 | |||||||||
| S1207-Brst,Adj,Endocrine+/-Everolimus | 1 | Y | 1 Blinded drug + Endocrine | 1900 | 896 | 182 | 88 | 49 | 19 | 6 | 09/12/2013 | 443 | 207 | |
| 2 Blinded drug + Endocrine | 901 | 177 | 84 | 42 | 16 | 4 | ||||||||
| 1797 | 359 | 172 | 91 | 35 | 10 | |||||||||
| S1222-Brst,Fulv. +/- Ever. +/- Anastr. | 1 | T | 1 Blinded treatment | 840 | 12 | 0 | 0 | 0 | 0 | 0 | 05/15/2014 | 13 | 3 | |
| 2 Blinded treatment | 12 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 3 Blinded treatment | 13 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 37 | 0 | 0 | 0 | 0 | 0 | |||||||||
| S1416-Brst, TNBC/BRCA, Cis+/- ABT-888 | 1 | Y | 1 Blinded Drug + Cisplatin | 333 | 138 | 43 | 15 | 12 | 3 | 1 | 09/15/2016 | 276 | 131 | |
| 2 Blinded Drug + Cisplatin | 142 | 48 | 21 | 14 | 3 | 2 | ||||||||
| 280 | 91 | 36 | 26 | 6 | 3 | |||||||||
| S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) | 1 | Y | 1 Tissue for PD-L1 testing | 1000 | 387 | 265 | 147 | 82 | 31 | 13 | 01/18/2017 | 478 | 211 | |
| 387 | 265 | 147 | 82 | 31 | 13 | |||||||||
| 2 | Y | 2 Observation | 1000 | 159 | 103 | 54 | 26 | 10 | 2 | 01/18/2017 | ||||
| 3 MK-3475 (Pembrolizumab) | 160 | 113 | 58 | 29 | 13 | 0 | ||||||||
| 319 | 216 | 112 | 55 | 23 | 2 | |||||||||
| Yes | A011106-Breast, Neoadj, ALTERNATE study | 1 | E | Total Registrations | 80 | 29 | 21 | 6 | 0 | 0 | 04/29/2014 | 120 | ||
| 80 | 29 | 21 | 6 | 0 | 0 | |||||||||
| E1Z11-Brst,Genetic Predictors of AIMSS | 1 | E | Total Registrations | 156 | 10 | 6 | 2 | 0 | 0 | 08/13/2013 | 23 | |||
| 156 | 10 | 6 | 2 | 0 | 0 | |||||||||
| NRGBR003-Brst,Adj,TNBC,AC -> WP +/- Carbo | 1 | E | Total Registrations | 67 | 19 | 11 | 5 | 1 | 0 | 10/16/2015 | 173 | |||
| 67 | 19 | 11 | 5 | 1 | 0 | |||||||||
| NRGBR005-Br, Stg II&IIIA, Post NAdj Chemo Br Conserv | 1 | E | Total Registrations | 6 | 6 | 6 | 4 | 2 | 0 | 06/22/2018 | 31 | 19 | ||
| 6 | 6 | 6 | 4 | 2 | 0 | |||||||||
| No | A011401-Breast, adj, Stage II/III HER2-, weight loss | 1 | E | Total Registrations | 195 | 103 | 49 | 18 | 4 | 0 | 10/05/2016 | 244 | ||
| 195 | 103 | 49 | 18 | 4 | 0 | |||||||||
| 2 | E | Total Registrations | 179 | 99 | 49 | 20 | 4 | 0 | 10/05/2016 | |||||
| 179 | 99 | 49 | 20 | 4 | 0 | |||||||||
| A011502-Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo | 1 | E | Total Registrations | 65 | 43 | 19 | 13 | 5 | 1 | 03/20/2017 | 457 | 226 | ||
| 65 | 43 | 19 | 13 | 5 | 1 | |||||||||
| A221405-Breast, ET interruption, Pregnancy Outcomes | 1 | E | Total Registrations | 13 | 5 | 4 | 1 | 0 | 0 | 05/08/2017 | 131 | 54 | ||
| 13 | 5 | 4 | 1 | 0 | 0 | |||||||||
| B51-Breast, Regional Nodal XRT | 1 | E | Total Registrations | 33 | 10 | 7 | 2 | 1 | 0 | 06/13/2014 | 204 | |||
| 33 | 10 | 7 | 2 | 1 | 0 | |||||||||
| B55-Brst, Adj Olaparib for BRCA,TNBC | 1 | E | Total Registrations | 68 | 19 | 9 | 2 | 0 | 0 | 12/15/2014 | 441 | 186 | ||
| 68 | 19 | 9 | 2 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 32 | 11 | 6 | 0 | 0 | 0 | 12/15/2014 | |||||
| 32 | 11 | 6 | 0 | 0 | 0 | |||||||||
| E2112-Brst,Adv,Exemestane+/-Entinostat | 1 | E | Total Registrations | 61 | 17 | 10 | 4 | 0 | 0 | 04/01/2015 | 175 | |||
| 61 | 17 | 10 | 4 | 0 | 0 | |||||||||
| EA1131-Brst, TNBC, Post-op Chemo vs Obs | 0 | E | Total Registrations | 23 | 8 | 5 | 5 | 1 | 0 | 11/12/2015 | 133 | |||
| 23 | 8 | 5 | 5 | 1 | 0 | |||||||||
| 1 | P | Total Registrations | 12 | 5 | 1 | 1 | 1 | 1 | 11/12/2015 | |||||
| 12 | 5 | 1 | 1 | 1 | 1 | |||||||||
| EA1151-Brst, Tomosynthesis Mammographic Screening | 1 | E | Total Registrations | 256 | 256 | 148 | 78 | 25 | 6 | 01/30/2018 | 159 | 76 | ||
| 256 | 256 | 148 | 78 | 25 | 6 | |||||||||
| NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA | 1 | E | Total Registrations | 1 | 0 | 0 | 0 | 0 | 0 | 09/22/2017 | 319 | 136 | ||
| 1 | 0 | 0 | 0 | 0 | 0 | |||||||||